Capricor Therapeutics (CAPR) Share-based Compensation (2010 - 2026)

Capricor Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 2198.62% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $19.0 million (up 1161.58% YoY), while the FY2025 annual figure was $13.4 million, down 34.4% from the prior year.
• Share-based Compensation for Q1 2026 stood at $5.9 million, up from $4.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $16.6 million in Q3 2024, with the low at -$7.5 million in Q4 2024.
• The 5-year median for Share-based Compensation is $1.8 million (2023), against an average of $2.9 million.
• The sharpest annual moves came in 2024 and 2026: Share-based Compensation plunged 501.22% in 2024, then soared 2198.62% in 2026.
• Capricor Therapeutics' Share-based Compensation stood at $1.1 million in 2022, then soared by 62.14% to $1.9 million in 2023, then slumped by 501.22% to -$7.5 million in 2024, then soared by 156.94% to $4.3 million in 2025, then soared by 39.15% to $5.9 million in 2026.
• Business Quant data shows CAPR's Share-based Compensation at $5.9 million in Q1 2026, $4.3 million in Q3 2025, and $8.9 million in Q2 2025.